


Petri Bio



*Tomorrow's drugs from
your inner bugs*

90% of all disease states are influenced by gut microbes, including:

- Inflammatory Bowel Disease
- Fatty Liver Disease
- Diabetes
- Heart Disease
- Alzheimer's Disease
- Parkinson's Disease
- Autism
- Epilepsy

Microbes that protect against these disease states are revealed by **gene sequencing**



But ~99% of microbes **fail to grow** in the lab for further study and development




???


Problem: millions of beneficial bacteria with potential to cure disease are left unstudied

At Petri Bio, we express these bacteria's genes cell-free, to get the first look at how they can be made into cures

We analyze the genetic sequence of these bacteria to predict and synthesize the most promising compounds



We test these compounds in tissue culture for therapeutic potential




Useful compounds can be marketed as biologic therapeutics,
or expressed in FDA-approved, food grade probiotics

Encapsulated Peptide
(therapeutic)



Engineered Probiotic
(supplement/food)



Advantages

- Using microbial-peptides as a drug library gives access to millions of new compounds not currently accessed by pharma
- Focusing on unculturable bacteria creates a competitive advantage comparing to other microbiome companies
- Cell-free expression approach enables high-throughput screening faster and cheaper

Pipeline and milestones

Indication	Product Maturity	Market Size
Viral Infection	<pre>graph LR; A[Bioinformatic Discovery] --> B[Candidates Generated]; B --> C[Prototype Manufactured]; C --> D[Patent Filed]; D --> E[Optimization And Testing];</pre>	<p>\$2.5 B USD / year</p>
Non-Alcoholic Steatohepatitis (NASH)	<pre>graph LR; A[Bioinformatic Discovery] --> B[Candidates Generated];</pre>	<p>>\$7 B USD / year By 2026</p>
Inflammatory Bowel Disease (IBD)	<pre>graph LR; A[Bioinformatic Discovery];</pre>	<p>\$15.9 B USD / year</p>

Our business model



Develop therapeutic candidates targeting three different markets



Strategic partnerships w/ pharma companies for drug development; generate early revenue from licensing fee & royalties



Clinical trials tested and FDA approved prescription medicine

Goal and milestones

- We are raising 400k for the next 9 months
- Deliverables:
 - Keep developing current candidates for lab-based proof-of-concepts;
 - File patents to protect the technology;
 - Build out the platform to search for therapies for more diseases

Our Founders



Shu Li, Ph.D.
Co-Founder & CEO

Genetic Engineer
8 papers, 3 patents
YC S17

shu@petribio.com



Joe Schinaman, Ph.D.
Co-Founder & CSO

Microbiome Scientist
6 papers, 1 patent
LA Biostart alumni

joe@petribio.com